A protein drug developer with roots in Germany continues to grow in Boston, MA, with the help of another partnership. Pieris Pharmaceuticals today cut a deal with AstraZeneca to develop a group of drugs for respiratory diseases, adding a new name to an already wide list of pharmaceutical partners.
Pieris (NASDAQ: PIRS) gets $45 million up front in the deal with the British pharma, which will work with the company to bring PRS-060, an experimental asthma drug, into human clinical testing. The Pieris drug will begin Phase 1 testing this year, at which point Pieris will get another $12.5 million,… Read more »
UNDERWRITERS AND PARTNERS
May 03, 2017 at 08:11PM
from Ben Fidler
No comments:
Post a Comment